ACCC's Emerging Companies Council

Abbott Oncology
Abbott Oncology
100 Abbott Park Road
Abbott Park, IL 60064
Tel: 847.937.6100

Abbott is a global, broad-based healthcare company devoted to discovering new medicines, new technologies, and new ways to manage health. Its products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. A comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.

Abbott is behind some of the world's most trusted names in infant, adult, and healthy living nutritional products, including Similac, Ensure, Glucerna, AdvantEdge, Body-for-LIFE and ZonePerfect. In addition to these well-known consumer brands, Abbott also offers medical nutritional products and feeding devices for patients with special dietary needs due to injury or illnesses such as cancer, respiratory conditions, and food allergies.

Abbott's broad range of medical diagnostic instruments and tests are used worldwide in hospitals, reference labs, blood banks, physician offices, clinics and at home to diagnose a range of serious health issues such as infectious diseases, cancer, diabetes and genetic conditions, as well as monitor other important indicators of health. The cornerstone of their diagnostic products is immunodiagnostics, the science of measuring the body's antigen/antibody reactions to detect diseases and other medical conditions. Abbott's molecular diagnostics help physicians detect genetic mutations in patients' genes and chromosomes to detect and manage disease. Hand-held point of care diagnostics and blood glucose monitoring devices provide healthcare professionals and patients with fast, convenient, and accurate test results.

Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
11080 CirclePoint Road Suite 200
Westminster, CO 80020
Tel: 303.426.6262

Allos Therapeutics, Inc., is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics.

Folotyn (pralatrexate injection) is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing Folotyn in other potential indications. Allos retains exclusive worldwide rights to Folotyn for all indications. The Company is headquartered in Westminster, Colorado.

Click here for patient assistance information.

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877
Tel: 203.798.9988

Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiary of Boehringer Ingelheim, headquartered in Germany, operates globally in 47 countries with approximately 39,800 employees. The company is committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Boehringer Ingelheim is building on its long-standing research and development capabilities and expertise in several other disease areas (e.g., respiratory, cardiovascular, virology and metabolic disorders), and the strong scientific foundation provided by its research and development centers worldwide. Several years ago, Boehringer Ingelheim started to engage in cancer research in response to the unmet medical needs of patients with cancer and has made advances in understanding cancer biology. With its cancer research and development program, Boehringer Ingelheim is committed to discovering and developing innovative cancer treatments that provide high therapeutic value for patients and healthcare providers. Building on breakthrough science to develop targeted therapies, small molecules and biologics, Boehringer Ingelheim is focusing its research on areas of unmet medical need, including lung, breast, ovarian, colorectal and prostate cancers, as well as lymphomas and leukemias.

Boehringer Ingelheim employs more than 200 scientists in its cancer research facility at the Boehringer Ingelheim Austria Regional Centre in Vienna to discover new cancer medicines. Promising drug candidates are developed by the non-clinical and clinical development organization of Boehringer Ingelheim, representing a team of nearly 400 professionals working in oncology. Their efforts, combined with those of leading experts in cancer research and medicine at universities and cancer hospitals, are focused on developing a range of next-generation therapeutics to combat cancer. Compounds under investigation in oncology focus on three areas: angiogenesis inhibitors, signal transduction inhibitors and cell-cycle kinase inhibitors.

EMD Serono
One Technology Place
Rockland, MA 02370
Phone: 800-283-8088

EMD Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical group. We strive to create value and benefit patients by transforming medical science into breakthrough solutions in our core therapeutic areas of neurodegenerative diseases, fertility and metabolic endocrinology, as well as oncology and autoimmune/inflammatory diseases as emerging areas of expertise.

EMD Serono, Inc. is growing its presence in oncology in the U.S, with a focus on developing novel first-in-class therapies targeting the cancer disease process. EMD Serono oncology research and development focuses on three areas: the tumor cell; the tumor environment; and the immune system.

Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
Phone: 650.556.9300
Fax: 650.556.1132

Company Information
Genomic Health, a life science company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.

The pioneering work of Genomic Health in molecular diagnostics has led to the Oncotype DX Breast Cancer Assay, a laboratory test that analyzes the expression level of 21 genes in a woman’s breast tumor sample. It is the first and only gene expression test that has demonstrated the ability to predict a patient’s likelihood to benefit from chemotherapy as well as her risk of experiencing a disease recurrence. Oncotype DX is recommended in both the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) clinical practice guidelines, including it in the standard of care for the majority of early-stage breast cancer patients.

At Genomic Health, we developed and follow a highly specialized process that not only adheres rigorously to CAP (College of American Pathologists) standards and CLIA (Clinical Laboratory Improvement Amendments) regulations, but also incorporates numerous real-time quality checks and periodic proficiency testing designed to produce a high level of accuracy in information that we deliver to physicians and patients.

Genomic Health is committed to compliance with applicable federal, state and local statutes and regulations that affect the operation of its business in its role as a provider of healthcare services, in order to conduct its activities with the utmost integrity and in accordance with the law. Genomic Health's compliance program furthers this commitment with internal controls and quality assurance processes that are designed to promote adherence to applicable federal and state laws.

Click here for patient assistance information.

Onyx Pharmaceuticals

Onyx Pharmaceuticals
249 E. Grand Avenue
South San Francisco, CA 94080
Phone: 650.266.0000

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to extending and enhancing the lives of patients with cancer and other serious illnesses. We are focused on developing innovative targeted therapies to transform the treatment of life-threatening diseases.

Our lead product, Nexavar® (sorafenib) tablets, is the only systemic therapy approved for unresectable liver cancer and has been established as an important treatment for advanced kidney cancer. Approved in more than 100 countries, Nexavar has benefited more than 200,000 patients to date and is currently being evaluated in a range of other cancers. Nexavar is an oral drug that inhibits key proteins involved in the growth and spread of cancer, is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals, Inc.

Beyond Nexavar, we are advancing carfilzomib, a selective next-generation proteasome inhibitor, in late-stage clinical development. In a broad range of clinical studies, carfilzomib has demonstrated encouraging activity together with durable disease control and long-term tolerability across a range of treatment settings and patient populations. These results suggest carfilzomib’s potential as a cornerstone of care for patients at every stage of their disease. Our new drug application (NDA) is currently in review with the FDA for potential accelerated approval in the U.S.

In addition, we are conducting a randomized Phase 3 study, known as the ASPIRE trial, in patients with relapsed multiple myeloma comparing carfilzomib in combination with lenalidomide and low-dose dexamethasone versus lenalidomide plus dexamethasone alone. This study is being performed to register carfilzomib worldwide in the setting of relapsed multiple myeloma. To support registration in Europe, we are currently conducting a Phase 3 study, known as the FOCUS trial, of single-agent carfilzomib in the same population of late-stage patients.

We are also developing two other novel proteasome inhibitors, including an oral protease inhibitor (ONX 0912) and an immunoproteasome inhibitor (ONX 0914). The proteasome has been validated as an important clinical target in cancer, and our goal is to develop next-generation agents whose high degree of specificity provides potential increased therapeutic efficacy and reduced off-target toxicities. In addition, we have the potential to receive milestone and royalty payments from PD 0332991, an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor being developed by Pfizer, formerly Warner-Lambert Company and an early collaborator of Onyx.

Onyx today has three major platforms for growth: our core asset Nexavar, our emerging proteasome inhibitor franchise, and our early stage pipeline. Accordingly, we have established a set of priorities directing our expansion and diversification: Maintain a strong financial profile; build a proteasome inhibitor franchise; sustain and increase Nexavar growth; and leverage pipeline assets. We believe Onyx is uniquely positioned within the biopharmaceutical industry, combining the commercial experience and strong business fundamentals of an established company with the innovation, flexibility, transparency, and collaborative approach of an entrepreneurial start-up.

Seattle Genetics
Seattle Genetics
21823 - 30th Drive S.E.
Bothell, WA 9802
Phone: 425-527-4000

Seattle Genetics is a biotechnology company advancing a broad pipeline of antibody-based therapies. In August 2011, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Adcetris (brentuximab vedotin) for two indications.

We are jointly developing brentuximab vedotin in collaboration with Millennium: The Takeda Oncology Company. Under the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the U.S. and Canada. We plan to submit our regulatory application to Canadian Health authorities in the first half of 2012 for relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Millennium has exclusive rights to commercialize the product candidate in all other countries. In June 2011, the European Medicines Agency (EMA) accepted for review Millennium's Marketing Authorization Application (MAA) for ADCETRIS for the treatment of relapsed or refractory HL and relapsed or refractory systemic ALCL.

In addition to ADCETRIS, Seattle Genetics has three clinical-stage ADC product candidates, SGN-75, ASG-5ME and ASG-22ME, which are in ongoing phase I trials. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Seattle Genetics has developed next generation ADCs that link the proven selectivity and activities of monoclonal antibodies with potent cytotoxic agents. Our proprietary technology employs synthetic tumor cell-killing agents called auristatins (such as MMAE and MMAF) and stable linkers that attach the auristatin to the antibody. Our linker systems are designed to be stable in the bloodstream and release the cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc.
1 First Avenue
Parris Building, #34
Navy Yard Plaza
Boston, MA 02129
Tel: 617.259.1970

ZIOPHARM Oncology, Inc., is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of small molecule cancer drugs. The Company is currently focused on three clinical programs.

Zymafos TM (palifosfamide, ZIO-201) is a novel molecule that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, ovarian, testicular and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance of ifosfamide and cyclophosphamide in certain cancers. It does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. Intravenous (IV) palifosfamide is currently in a Phase II randomized trial to treat soft tissue sarcoma. An oral form of palifosfamide has been developed preclinically and is expected to enter clinical study in 2009.

Zybulin TM (indibulin, ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. Indibulin will also be applicable to dose density mathematical modeling. Indibulin has shown early activity in a Phase I study as a single agent in many types of solid tumors. Indibulin is also currently in the Phase I portion of Phase I/II trials in combination with Tarceva® and Xeloda®. Preclinical study continues with both dose density and metronomic administration.

Zinapar TM (darinaparsin, ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. Preclinical and Phase I and II results to date demonstrate that darinaparsin is much less toxic than other forms of arsenic. Intravenous darinaparsin continues to be studied in a Phase II hematology trial showing activity in lymphomas and in Phase I study with oral administration. Darinaparsin has been well tolerated in all trials to date.